Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
Study Details
Study Description
Brief Summary
Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Microtransplantation, which combines chemotherapy with adoptive infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC). Data from more than 70 elderly AML patients who received microtransplantation in Beijing showed that the remission rate and 2-year disease-free survival (DFS) reach 75-82% and 32-39% respectively, and microchimerisms (donor cells<1%) were detected without GVHD. The results have been clinically validated in several other centers in China, United States and Australia.
In this study, azacytidine, decitabine, BCL / 2 inhibitor and other drugs combined with micro transplantation were used in elderly AML in order to improve the curative effect.
Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: MST for unfit Induction chemotherapy can use azacytidine combined with low-dose cytarabine, or azacytidine combined with BCL / 2 inhibitor, and infuse modified peripheral blood hematopoietic stem cells after chemotherapy. Consolidation chemotherapy used azacytidine combined with low-dose cytarabine. After chemotherapy, modified peripheral blood hematopoietic stem cells were infused and repeated for 3 courses. |
Biological: microtransplantation, HLA-mismatched donor peripheral stem cell infusion
HLA-mismatched donor peripheral stem cell infusion
Other Names:
Drug: Azacitidine
azacytidine 50-75mg/m2
Other Names:
Drug: Venetoclax
Venetoclax 100-300mg/d ×3d，400mg 4-28d
Other Names:
|
Outcome Measures
Primary Outcome Measures
- the remission rate [2month]
①bone marrow: blasts <5% (with a count of at least 200 Nucleated cells).②Hemogram: absolute neutrophil count of more than 1.0×109/L，platelets of >100×109/L. ③Clinical: Without the signs and symptoms caused by leukemia infiltration d , and independent of transfusion;
Secondary Outcome Measures
- Disease Free Survival [2 year]
Measured from complete remission to the date of death or the date of last follow-up examination;
- Overall Survival [2 year]
measured from the Date of beginning therapy to the date of death or the date of last follow-up examination;
Other Outcome Measures
- treatment-related mortality [2 year]
Early mortality: death within 4 weeks after initiation of induction therapy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have elderly (60-85 ages) AML pathologically confirmed per WHO guidelines.
-
Patients have not been treated before.
-
Patients must have ECOG Performance status of 0,1,or 2. If ECOG 2.
-
Patients must have a HLA mismatched donor who should be able to provide informed consent.
-
All genders and races are eligible.
-
ALT and AST≤3 ×ULN, TBIL≤1.5 × ULN, Cr≤2 ×ULN or CrCl≥40 mL/min
-
By means of ultrasonic Heartbeat map or multiple gated acquisition (MUGA) scanning determination of LVEF in the normal range.
-
Donors must be able to safely undergo leukapheresis.
Exclusion Criteria:
-
received operation 4 weeks before randomization
-
acute promyelocytic leukemia,Myeloid sarcoma, chronic myeloid leukemia in accelerated phase and blastic phase;
-
active CNS disease, pregnancy, or other major medical or psychiatric illnesses that could compromise tolerance to this protocol
-
occurred stroke or intracranial hemorrhage within 6 months before randomization.
-
Require the use of warfarin or equivalent of vitamin K antagonists (such as phenprocoumon) anticoagulant.
-
There is clinical significance of cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months before randomization, or any heart function grade 3 (moderate) or 4 (severe ) heart disease in accordance with the functional classification method of New York Heart Association (NYHA).
-
Known to have the following history: human immunodeficiency virus (HIV) or active hepatitis C virus or hepatitis B virus infection
-
Any situation processed by the PI that will be damaged to the patients safety.
-
Patients and / or authorized family member refuse to sign the consent.
-
attend other clinical researchers in 3 months.
-
Donors exclusion criteria include:active infection or malignancy, cardiovascular instability, severe anemia, severe coagulation disorder, pregnancy, inadequate venous access, inability to provide consent, or any other condition deemed unsafe by the treatment staff.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The fifth medical center of PLA General Hospital | Beijing | Beijing | China |
Sponsors and Collaborators
- guomei
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MST-EAML2020